JCJeong June Choi

Jeong June Choi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jeong June Choi has a total of 66 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Neohesperidin from Aurantii Fructus Immaturus Exerts Antidepressant-Like Effects and Modulates Glucocorticoid Receptor Signaling in a Chronic Stress Model

    by Eunho Chun, Soojung Yoon, Hamid Iqbal, Sun Yeou Kim, Seon Hee Kim, Jeong June Choi, Mirim Jin

    Depression, a mood disorder characterized by persistent negative emotions and impaired functioning, is associated with dysregulation of the hypothalamic–pituitary–adrenal (HPA) axis and glucocorticoid receptor (GR) dysfunction. Aurantii Fructus Immaturus (AFI), the immature fruit of Citrus aurantium Linné, has been used in East Asian herbal medicine, and neohesperidin (NHD), a principal constituent of AFI, has been studied for its antidepressant properties. This study aimed to elucidate the mechanisms underlying the antidepressant effects of NHD, focusing on its ability to enhance GR expression and activity, thereby normalizing HPA axis function and mitigating neuroinflammation. AFI extract and its component NHD ameliorated depression-like behaviors in chronic restraint stress mice with normalized plasma corticosterone (CORT) levels. Moreover, NHD treatment reduced hippocampal expression of proinflammatory cytokine genes ( TNFA , IL6 , IL1A , and IL1B ) while enhancing GR expression, particularly the NR3C1 exon 1 7 and 1 10 variants homologous to human GR variants implicated in depression. In cultured cells, NHD not only reversed CORT-induced neurite atrophy in N2a cells but also suppressed lipopolysaccharide-induced cytokine release in BV2 microglia. Notably, gene silencing of the GR via siRNA abrogated these neuritogenic and antineuroinflammatory effects, demonstrating that NHD exerts its antidepressant and neuroinflammation-suppressive actions in a GR-dependent manner. These findings suggest a promising therapeutic potential for AFI and NHD in stress-related depressive disorders, offering a multi-target approach that addresses both stress response and neuroinflammation through modulation of GR expression.


  • Open Access

    1,4-Naphthoquinone improves depressive-like behaviors by modulating neuronal factors and neuroinflammatory mediators

    by Joo Hye Sim, Hye Jin Choi, Ohhyeon Kwon, Taeyeon Kim, Doheon Lee, Jeong June Choi


  • Open Access

    Comparison of Plasma Metabolites From Patients With Non-Small Cell Lung Cancer by Erlotinib Treatment and Skin Rash

    by Won Kil Lee, Jisoo Myong, Eunbin Kwag, Younmin Shin, Ji Woong Son, Byong Chul Yoo, Byoung-Soo Kim, Hwa-Seung Yoo, Jeong June Choi

    Erlotinib is a necessary anticancer treatment for non-small cell lung cancer (NSCLC) patients yet it causes severe side effects such as skin rash. In this study, researchers compared the untargeted compound profiles before and after erlotinib administration to observe changes in blood metabolites in NSCLC patients. The levels of 1005 substances changed after taking erlotinib. The levels of 306 and 699 metabolites were found to have increased and decreased, respectively. We found 5539 substances with peak area differences based on the presence of skin rash. Carbohydrate, amino acid, and vitamin metabolic pathways were altered in response to the onset of erlotinib-induced skin rash. Finally, this study proposed using plasma metabolites to identify biomarker(s) induced by erlotinib, as well as target molecule(s), for the treatment of dermatological toxic effects.


  • Open Access

    Selective Immune Modulating Activities of Viscum album and Its Components; A Possibility of Therapeutics on Skin Rash Induced by EGFR Inhibitors

    by Hye Jin Choi, So-Jung Park, You Na Choi, Soo-Dam Kim, Eun-Bin Kwag, Si-Yeon Song, Ji Hye Park, Jin Kyu Kim, Changon Seo, Jeong June Choi, et al.

    Viscum album var. coloratum (Kom.) Ohwi is a traditional herbal medicine used in East Asia to treat hypertension, skeletal muscle disorders, and cancer. The inhibitory effects of Viscum album (VA) extract on chemokines and its therapeutic potential in erlotinib-induced skin rash were investigated in this study. ELISA was used to measure the levels of chemokines, MCP-1 and RANTES, which are thought to be mediators of erlotinib-induced skin rash in RAW264.7 cells. Western blot analysis was used to look into the activation of signaling pathways like AKT, MAPK, and EGF. In order to investigate the active compounds in VA extract, solvent fractionation and preparative HPLC were performed sequentially. VA extract significantly reduced the production of TNF-α, MCP-1, and RANTES but not IL-1. Furthermore, macrophage transmigration was inhibited without causing cell toxicity. VA extract had no effect on the phosphorylation of EGF receptors stimulated by EGF or suppressed by erlotinib in both A549, a non-small cell lung cancer cells, and Hacat, a human skin keratinocyte. The isolated viscumneoside III and viscumneoside V from VA extract significantly suppressed the expression of MCP-1, according to activity guided fractionation with organic solvent fractionation and preparative HPLC. These findings suggest that VA extract and its active compounds, viscumneoside III and viscumneoside V, regulate MCP-1 production and may have the potential to suppress erlotinib-induced skin toxicity by modulating macrophage activity without neutralizing anti-cancer efficacy.


  • Open Access

    Exogenous Transforming Growth Factor-β in Brain-Induced Symptoms of Central Fatigue and Suppressed Dopamine Production in Mice

    by Won Kil Lee, Yeongyeong Kim, Heejin Jang, Joo Hye Sim, Hye Jin Choi, Younmin Shin, Jeong June Choi

    Myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS) is one of the most refractory diseases in humans and is characterized by severe central fatigue accompanied with various symptoms that affect daily life, such as impaired memory, depression, and somatic pain. However, the etiology and pathophysiological mechanisms of CFS remain unknown. To investigate the pathophysiological role of transforming growth factor (TGF)-β1, we injected a cytokine into the lateral ventricle of a C57BL/6 mouse. The intracranial injection of TGF-β1 increased the immobility duration in a forced swimming test (FST) and time spent at the closed arm in elevated plus maze (EPM) analysis. The mice injected with TGF-β1 into their brain showed increased sensitivity to pain in a von Frey test, and had a decreased retention time on rotarod and latency time in a bright box in a passive avoidance test. In addition, the serum levels of muscle fatigue biomarkers, lactate dehydrogenase (LDH) and creatine kinase (CK), were significantly increased after administration of TGF-β1. Intracranial injection of TGF-β1 significantly reduced the production of tyrosine hydroxylase (TH) in the ventral tegmental area, accompanied by a decreased level of dopamine in the striatum. The suppression of TH expression by TGF-β1 was confirmed in the human neuroblastoma cell line, SH-SY5Y. These results, which show that TGF-β1 induced fatigue-like behaviors by suppressing dopamine production, suggest that TGF-β1 plays a critical role in the development of central fatigue and is, therefore, a potential therapeutic target of the disease.


  • Dietary Epigallocatechin-3-Gallate Alters the Gut Microbiota of Obese Diabetic db/db Mice: Lactobacillus Is a Putative Target

    by Jong-Min Park, Younmin Shin, Seung Hyung Kim, Mirim Jin, Jeong June Choi

    Obesity results in the progression of metabolic disorders, and especially type 2 diabetes mellitus (T2DM), and the gut microbiota have been implicated in the development of T2DM. This study investigated the effect of epigallocatechin-3-gallate (EGCG) on structural changes to the gut microbiota of obese diabetic db/db mice. db/db mice were subjected to a control and EGCG (10, 50, and 100 mg/kg) diet for 8 weeks. Glucose homeostasis and the structure and composition of the gut microbiota were measured. EGCG inhibited the increases in body weight and fasting blood glucose levels. Similarly, it resulted in remarkable improvements in glucose tolerance. Based on lipid profiles, EGCG decreased serum cholesterol and low-density lipoprotein (LDL) levels, and increased the high-density lipoprotein/LDL ratio. In addition, upon fecal microbiota analysis, this compound significantly increased the Firmicutes:Bacteroidetes ratio at the phylum level and increased Lactobacillus abundance at the genus level. Especially, its administration increased abundances of the Lactobacillus gasseri, Lactobacillus intestinalis, and Lactobacillus reuteri. We also found that EGCG increased Christensenellaceae abundance and decreased Enterobacteriaceae and Proteobacteria abundance at the family level. EGCG improves glucose homeostasis in diabetic mice. Its beneficial effects on glucose homeostasis are likely associated with alterations to the gut microbiota. Furthermore, the enrichment of probiotics (Lactobacillus) might be a potential mechanism underlying the effects of EGCG on glucose homeostasis.


  • Open Access

    Anti-diabetic Effects of Wild Soybean Glycine Soja Seed Extract on Type 2 Diabetic Mice and Human Hepatocytes induced Insulin Resistance

    by Eunjung Son, Hye Jin Choi, Seung-Hyung Kim, Dong-Gyu Jang, Jimin Cha, Jeong June Choi, Mee Ree Kim, Dong-Seon Kim

    Anti-diabetic effects of Glycine soja seed extract (GS) on Type 2 diabetes mellitus mouse model and human hepatocytes induced insulin resistance were investigated. 3 weeks old db/db mice were divided into 5 groups (n = 6) including two control groups and 3 GS treated groups with different doses. Oral administration of GS for 6 weeks to diabetic db/db mice reduced blood glucose level significantly in a dose dependent manner by 44.7% (300 mg/kg/day), 30.9% (150 mg/kg/day) and 21.1% (75 mg/kg/day). GS treatment also lowered significantly plasma level of HbA1c, insulin, IGF-1 and leptin, and increased that of adiponectin. GS treatment activated AMPK, and down-regulated GLUT2 in liver tissues of mice while up-regulated GLUT4 in muscle tissues of mice. In in vitro study with insulin resistance induced human hepatocyte, GS treatment increased glucose uptake and increased the activities of Akt and PPAR-γ in response to insulin. Treatment of GS appears to reduce blood glucose level by regulating energy metabolism positively through various metabolic pathways and reducing insulin resistance in Type 2 diabetes mellitus.


  • Open Access

    So-Ochim-Tang-Gamibang, a Traditional Herbal Formula, Ameliorates Depression by Regulating Hyperactive Glucocorticoid Signaling In Vitro and In Vivo

    by Mirim Jin, Sun Young Park, Hye Jin Choi, Younmin Shin, Eunho Chun, In Chul Jung, Jeong June Choi

    So-ochim-tang-gamibang (SOCG) is a Korean traditional medicine; it has previously been shown to be safe and effective against depression. Persistently increased levels of circulating glucocorticoids have been considered as a pathological mechanism for depression and associated with decreased neurotrophic factors in the hippocampus. This study investigated whether SOCG controls the hyperactivity of the hypothalamic‐pituitary‐adrenal (HPA) axis and the molecular mechanisms underlying its effects in vivo and in vitro. Wistar Kyoto (WKY) rats were subjected to restraint stress, where SOCG was orally administered to the animals for 2 weeks. An open field test (OFT), forced swimming test (FST), and sucrose preference test (SPT) were performed to explore the antidepressant activity of SOCG in WKY rats. Plasma levels of HPA axis hormones were measured by ELISA or western blotting analysis. The expression levels or activation of HPA axis‐related signaling molecules such as brain‐derived neurotrophic factor (BDNF), cAMP response element‐binding protein (CREB), extracellular regulated kinase (ERK), and glucocorticoid receptors (GRs) in the brain were determined by real‐time PCR and western blotting analysis. Furthermore, a corticosterone‐ (CORT‐) induced cell injury model was established using SH‐SY5Y cells to explore the antidepressive effects of SOCG in vitro. The results of the OFT, FST, and SPT revealed that SOCG ameliorated depressive‐like behaviors in the WKY rats. The blood plasma levels of HPA axis hormones such as CORT, CORT‐releasing hormone (CRH), and adrenocorticotrophic hormone were downregulated by SOCG. On the other hand, SOCG upregulated the phosphorylation of CREB and ERK in both the rat hippocampus and CORT‐treated SH‐SY5Y cells. Moreover, it also increased the GR expression. These results suggested that SOCG may improve depression by controlling hyperactive glucocorticoid signaling via the downregulation of HPA axis hormones and upregulation of GR.